Cristiana Bergamini

List of Publications by Year
in descending order

39 papers	1,914 citations	361413 20 h-index	345221 36 g-index
39 all docs	39 docs citations	39 times ranked	2783 citing authors

#	Article	IF	Citations
1	High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 5630-5636.	1.6	605
2	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncology, 2009, 45, 574-578.	1.5	184
3	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncology, 2009, 45, 986-990.	1.5	144
4	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptorâ€“positive salivary gland cancers. Head and Neck, 2016, 38, 724-731.	2.0	104
5	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Annals of Oncology, 2012, 23, 1832-1837.	1.2	97
6	Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. Oral Oncology, 2017, 66, 58-63.	1.5	90
7	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. European Journal of Cancer, 2016, 69, 158-165.	2.8	66
8	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. Clinical Cancer Research, 2016, 22, 3961-3970.	7.0	65
9	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. Cancer, 2020, 126, 1888-1894.	4.1	54
10	Effects of Treatment Intensification on Acute Local Toxicity During Radiotherapy for Head and Neck Cancer: Prospective Observational Study Validating CTCAE, Version 3.0, Scoring System. International Journal of Radiation Oncology Biology Physics, 2008, 70, 330-337.	0.8	48
11	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 959-966.	0.8	48
12	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 57-75.	3.3	46
13	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. Oral Oncology, 2016, 54, 54-57.	1.5	46
14	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. Annals of Oncology, 2011, 22, 2495-2500.	1.2	31
15	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head and Neck, 2019, 41, 3670-3676.	2.0	29
16	Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. Future Oncology, 2013, 9, 103-114.	2.4	28
17	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Annals of Oncology, 2007, 18, 601-602.	1.2	26
18	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. Oral Oncology, 2018, 86, 266-272.	1.5	26

#	Article	IF	Citations
19	Temporal course and predictive factors of analgesic opioid requirement for chemoradiationâ€induced oral mucositis in oropharyngeal cancer. Head and Neck, 2016, 38, E1521-7.	2.0	25
20	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptorâ€“Expressing Salivary Gland Cancer: A Phase II Trial. Journal of Clinical Oncology, 2021, 39, 4061-4068.	1.6	24
21	Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. Oral Oncology, 2014, 50, 884-887.	1.5	20
22	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Oral Oncology, 2017, 69, 33-37.	1.5	16
23	Targeted therapy in head and neck cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2011, 19, 132-137.	1.8	12
24	Preemptive treatment with XonridÂ®, a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study. Supportive Care in Cancer, 2017, 25, 1787-1795.	2.2	12
25	A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2479-2487.	2.5	12
26	Bleeding complications in patients with squamous cell carcinoma of the head and neck. Head and Neck, 2021, 43, 2844-2858.	2.0	12
27	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. Expert Opinion on Investigational Drugs, 2019, 28, 435-443.	4.1	8
28	Is Restoring Platinum Sensitivity the Best Goal for Cetuximab in Recurrent/Metastatic Nasopharyngeal Cancer?. Journal of Clinical Oncology, 2005, 23, 7757-7758.	1.6	7
29	Health careâ€“associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. Head and Neck, 2016, 38, E1009-13.	2.0	6
30	Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.. Journal of Clinical Oncology, 2022, 40, 9520-9520.	1.6	5
31	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. Disease Markers, 2017, 2017, 1-9.	1.3	4
32	Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series. Tumori, 2021, 107, 030089162095284.	1.1	4
33	Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. Future Oncology, 2014, 10, 2111-2120.	2.4	3
34	A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy of AqualiefTM Mucoadhesive Tablets in Head and Neck Cancer Patients Who Developed Radiation-Induced Xerostomia. Cancers, 2021, 13, 3456.	3.7	3
35	Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.8	3
36	Safety of Combination Treatment with Imatinib Mesylate, Carboplatin, and Cetuximab in a Patient with Multiple Cancers: A Case Report. Tumori, 2016, 102, S1-S2.	1.1	1

#	Article	IF	Citations
37	Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas?. Oral Oncology, 2005, 41, 219-221.	0.7	0
38	Comment on â€œAcute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysisâ€, by Rades et coll.. Oral Oncology, 2010, 46, 888.	1.5	0
39	Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic. Tumori, 2021, , 030089162110079.	1.1	0